呼吸道同胞细胞病毒感染:一个更新
Akshita Soni1, S K Kabra1, Rakesh Lodha2
1Department of Pediatrics, AIIMS, New Delhi, 110029, India.
Indian journal of pediatrics
|June 16, 2023
概括
呼吸道同胞性病毒 (RSV) 在婴儿中引起显著的下呼吸道感染. 最近批准的RSV疫苗为老年人预防提供了新的希望.
科学领域:
- 儿科 儿科 儿科
- 传染性疾病 传染性疾病
- 免疫学 免疫学 免疫学
背景情况:
- 呼吸道同胞病毒 (RSV) 是婴儿下呼吸道感染 (LRTI) 的主要原因.
- RSV影响所有年龄组,但对1岁以下的儿童构成最大风险,特别是早产婴儿或患有潜在疾病的婴儿.
- 在COVID-19后,RSV发病率可能会增加,这可能是由于"免疫债务".
研究的目的:
- 审查儿童RSV感染的临床表现和管理.
- 突出最近RSV疫苗开发和批准方面的进展.
主要方法:
- 关于RSV流行病学,临床表现和治疗方式的文献综述.
- 最近对成人和孕妇的RSV疫苗的临床试验结果的摘要.
- 包括有关老年人新批准的RSV疫苗的信息.
主要成果:
- 感染RSV的症状包括发烧,咳和流鼻,可能导致诸如支气管炎或肺炎等严重疾病.
- 支持性护理,包括严重病例的氧气治疗或机械通风,是主要的治疗策略.
- 两种RSV疫苗 (GSK的Arexvy和Pfizer的ABRYSVO) 现在已获得FDA批准用于老年人.
结论:
- 虽然大多数儿童在几周内从RSV中恢复过来,但严重的病例需要住院和密集的支持性护理.
- 有望的RSV疫苗候选人已经出现,最近的批准标志着对弱势群体,特别是老年人预防策略的重要一步.
更多相关视频
相关概念视频
Common Respiratory Disorders
714
Respiratory disorders, a prevalent health concern globally, are generally divided into two primary categories: upper and lower respiratory tract disorders. The categorization is based on the area of the respiratory system they affect.
Upper respiratory disorders impact the airways above the vocal cords, encompassing areas like the nose, sinuses, and throat. Various conditions fall under this category, including the common cold and allergic rhinitis. These disorders can stem from several causes,...
Upper respiratory disorders impact the airways above the vocal cords, encompassing areas like the nose, sinuses, and throat. Various conditions fall under this category, including the common cold and allergic rhinitis. These disorders can stem from several causes,...
714
Acute Respiratory Failure-V
169
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
169
Acute Respiratory Failure-II
287
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
287
Acute Respiratory Failure-I
253
Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
253
Acute Respiratory Failure-III
234
Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
234
Pneumonia IV: Management
399
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
399


